Literature DB >> 17562933

Application of automated medial temporal lobe atrophy scale to Alzheimer disease.

Basil H Ridha1, Josephine Barnes, Laura A van de Pol, Jonathan M Schott, Richard G Boyes, Musib M Siddique, Martin N Rossor, Philip Scheltens, Nick C Fox.   

Abstract

OBJECTIVE: To compare an automated intensity-based measure of medial temporal atrophy in Alzheimer disease (AD) with existing volumetric and visually based methods.
DESIGN: Longitudinal study comparing a medial temporal atrophy measure with 2 criterion standards: (1) total hippocampal (HC) volume adjusted for total intracranial volume and (2) standard visual rating scale of medial temporal atrophy.
SETTING: Cognitive disorders specialist clinic. PARTICIPANTS: Forty-seven patients with AD and 26 age- and sex-matched controls. INTERVENTION: Subjects were scanned using volumetric T1-weighted magnetic resonance imaging at baseline and 1 year later. MAIN OUTCOME MEASURE: Automated Medial Temporal Lobe Atrophy Scale (ATLAS) score, derived from dividing mean intensity of a standardized perihippocampal volume by that of a standardized pontine volume.
RESULTS: Patients with AD had significantly reduced ATLAS scores and HC volumes and increased visual rating scores at baseline and repeat scanning. Rates of HC atrophy and decline in the ATLAS score were significantly higher in patients with AD compared with controls. The ATLAS scores were significantly correlated with HC volumes and visual rating scores. With specificity set at 85%, the sensitivities of HC volume and visual rating scale score were similar (84% and 86%, respectively), whereas ATLAS score had a lower sensitivity (73%). At repeat scanning, all 3 measures had similar sensitivities (86%-87%). Rate of decline in the ATLAS score required a similar sample size to HC atrophy rate to provide statistical power to clinical trials, but being automated, it is less labor intensive.
CONCLUSIONS: Like the visual rating scale, ATLAS is a simple medial temporal atrophy measure, which has the additional advantage of being able to track AD progression on serial imaging.

Entities:  

Mesh:

Year:  2007        PMID: 17562933     DOI: 10.1001/archneur.64.6.849

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  14 in total

Review 1.  Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives.

Authors:  Harald Hampel; Richard Frank; Karl Broich; Stefan J Teipel; Russell G Katz; John Hardy; Karl Herholz; Arun L W Bokde; Frank Jessen; Yvonne C Hoessler; Wendy R Sanhai; Henrik Zetterberg; Janet Woodcock; Kaj Blennow
Journal:  Nat Rev Drug Discov       Date:  2010-07       Impact factor: 84.694

2.  Is radiological evaluation as good as computer-based volumetry to assess hippocampal atrophy in Alzheimer's disease?

Authors:  Claire Boutet; Marie Chupin; Olivier Colliot; Marie Sarazin; Gurkan Mutlu; Aurélie Drier; Audrey Pellot; Didier Dormont; Stéphane Lehéricy
Journal:  Neuroradiology       Date:  2012-07-11       Impact factor: 2.804

3.  Diagnostic performance of hippocampal volumetry in Alzheimer's disease or mild cognitive impairment: a meta-analysis.

Authors:  Ho Young Park; Chong Hyun Suh; Hwon Heo; Woo Hyun Shim; Sang Joon Kim
Journal:  Eur Radiol       Date:  2022-05-04       Impact factor: 7.034

4.  Automatic analysis of medial temporal lobe atrophy from structural MRIs for the early assessment of Alzheimer disease.

Authors:  Piero Calvini; Andrea Chincarini; Gianluca Gemme; Maria Antonietta Penco; Sandro Squarcia; Flavio Nobili; Guido Rodriguez; Roberto Bellotti; Ezio Catanzariti; Piergiorgio Cerello; Ivan De Mitri; Maria Evelina Fantacci
Journal:  Med Phys       Date:  2009-08       Impact factor: 4.071

5.  MIRIAD--Public release of a multiple time point Alzheimer's MR imaging dataset.

Authors:  Ian B Malone; David Cash; Gerard R Ridgway; David G MacManus; Sebastien Ourselin; Nick C Fox; Jonathan M Schott
Journal:  Neuroimage       Date:  2012-12-28       Impact factor: 6.556

6.  MTA index: a simple 2D-method for assessing atrophy of the medial temporal lobe using clinically available neuroimaging.

Authors:  Manuel Menéndez-González; Alfonso López-Muñiz; José A Vega; José M Salas-Pacheco; Oscar Arias-Carrión
Journal:  Front Aging Neurosci       Date:  2014-03-24       Impact factor: 5.750

7.  A comparison of measurement methods of hippocampal atrophy rate for predicting Alzheimer's dementia in the Aberdeen Birth Cohort of 1936.

Authors:  Arnab K Rana; Anca-Larisa Sandu; Kenna L Robertson; Christopher J McNeil; Lawrence J Whalley; Roger T Staff; Alison D Murray
Journal:  Alzheimers Dement (Amst)       Date:  2016-12-23

Review 8.  A Systematic Review of Longitudinal Studies Which Measure Alzheimer's Disease Biomarkers.

Authors:  Emma Lawrence; Carolin Vegvari; Alison Ower; Christoforos Hadjichrysanthou; Frank De Wolf; Roy M Anderson
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

Review 9.  Epidemiology of Alzheimer's disease: occurrence, determinants, and strategies toward intervention.

Authors:  Chengxuan Qiu; Miia Kivipelto; Eva von Strauss
Journal:  Dialogues Clin Neurosci       Date:  2009       Impact factor: 5.986

Review 10.  Vascular dementia: Diagnostic criteria and supplementary exams. Recommendations of the Scientific Department of Cognitive Neurology and Aging of the Brazilian Academy of Neurology. Part I.

Authors:  Eliasz Engelhardt; Carla Tocquer; Charles André; Denise Madeira Moreira; Ivan Hideyo Okamoto; José Luiz de Sá Cavalcanti
Journal:  Dement Neuropsychol       Date:  2011 Oct-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.